

Switch NRTIs to Tenofovir DF-Emtricitabine or Abacavir-Lamivudine  
**STEAL**

# Switch NRTIs to Tenofovir DF-Emtricitabine or Abacavir-Lamivudine

## STEAL: Study Design

### Study Design: STEAL

- **Background:** 96-week, randomized, open-label, non-inferiority trial comparing a switch of the NRTI backbone to either TDF-FTC or ABC-3TC in virologically suppressed persons
- **Inclusion Criteria:**
  - Adults with HIV infection
  - Receiving stable cART including 2 NRTI's plus a boosted PI or NNRTI
  - HIV RNA <50 copies/mL for  $\geq 12$  weeks
  - Estimated GFR  $\geq 70$  mL/min
  - HLA-B\*5701 negative or already receiving and tolerating ABC
  - Not receiving TDF for hepatitis B coinfection treatment

**Switch NRTI's to TDF-FTC**  
(n = 178)


**Switch NRTI's to ABC-3TC**  
(n = 179)

STEAL = **S**implification to **T**enofovir DF-**E**mtricitabine or **A**bacavir-**L**amivudine

# Switch NRTIs to Tenofovir DF-Emtricitabine or Abacavir-Lamivudine

## STEAL: Results

Week 96 Virologic Failures (Intention-to-Treat Analysis)




Source: Martin A, et al. Clin Infect Dis. 2009;49:1591-1601.

# Switch NRTIs to Tenofovir DF-Emtricitabine or Abacavir-Lamivudine

## STEAL: Results

Week 96: Change in Plasma Lipids from Baseline



# Switch NRTIs to Tenofovir DF-Emtricitabine or Abacavir-Lamivudine

## STEAL: Results

| STEAL: Results, Adverse Events (AE's)                                                                                                                                        |                            |                            |         |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|----------------------------|---------|
|                                                                                                                                                                              | TDF-FTC<br>+ [PI or NNRTI] | ABC-3TC<br>+ [PI or NNRTI] | P Value |
| Serious non-AIDS events                                                                                                                                                      | 4                          | 14                         | 0.018   |
| Cardiovascular events                                                                                                                                                        | 1                          | 8                          | 0.048   |
| Lipid-related event <sup>1</sup>                                                                                                                                             | 19                         | 40                         | 0.003   |
| Bone-related event <sup>2</sup>                                                                                                                                              | 27                         | 14                         | 0.032   |
| <sup>1</sup> New lipid-lowering therapy, or significant increase in LDL or decrease in HDL<br><sup>2</sup> Incident osteopenia or osteoporosis or new antiresorptive therapy |                            |                            |         |

# Switch NRTIs to Tenofovir DF-Emtricitabine or Abacavir-Lamivudine

## STEAL: Conclusions

**Conclusion:** “In this population, TDF-FTC and ABC-3TC had similar virological efficacy, but ABC-3TC was associated with more serious non-AIDS events, particularly cardiovascular events.”

# Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

*The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.*

